S. Charleson
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Asthma and respiratory diseases, Inflammatory mediators and NSAID effects, Estrogen and related hormone effects, Synthesis and biological activity, Allergic Rhinitis and Sensitization
Most-Cited Works
- → Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts(1996)465 cited
- → Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2(2001)457 cited
- → The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor(1999)427 cited
- → Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles(1999)398 cited
- → 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.(1993)395 cited
- → L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor(1989)328 cited
- → Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor(1997)326 cited
- → 5‐lipoxygenase‐activating protein is an arachidonate binding protein(1993)228 cited
- → Multiple opiate receptors: Differential binding of μ, κ and δ agonists(1981)204 cited
- → Urinary leukotriene E4 levels during early and late asthmatic responses(1990)196 cited